These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23025660)

  • 21. Live-attenuated lentivirus immunization modulates innate immunity and inflammation while protecting rhesus macaques from vaginal simian immunodeficiency virus challenge.
    Genescà M; Ma ZM; Wang Y; Assaf B; Qureshi H; Fritts L; Huang Y; McChesney MB; Miller CJ
    J Virol; 2012 Sep; 86(17):9188-200. PubMed ID: 22696662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.
    Kato S; Shida H; Okamura T; Zhang X; Miura T; Mukai T; Inoue M; Shu T; Naruse TK; Kimura A; Yasutomi Y; Matsuo K
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33087465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoprofiling Correlates of Protection Against SHIV Infection in Adjuvanted HIV-1 Pox-Protein Vaccinated Rhesus Macaques.
    Lu P; Guerin DJ; Lin S; Chaudhury S; Ackerman ME; Bolton DL; Wallqvist A
    Front Immunol; 2021; 12():625030. PubMed ID: 34046030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunity and protection by live attenuated HIV/SIV vaccines.
    Wodarz D
    Virology; 2008 Sep; 378(2):299-305. PubMed ID: 18586297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy.
    Palermo RE; Patterson LJ; Aicher LD; Korth MJ; Robert-Guroff M; Katze MG
    J Virol; 2011 Jan; 85(2):1099-116. PubMed ID: 21068249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.
    Iyer SS; Gangadhara S; Victor B; Shen X; Chen X; Nabi R; Kasturi SP; Sabula MJ; Labranche CC; Reddy PB; Tomaras GD; Montefiori DC; Moss B; Spearman P; Pulendran B; Kozlowski PA; Amara RR
    J Virol; 2016 Oct; 90(19):8842-54. PubMed ID: 27466414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.
    Burton SL; Kilgore KM; Smith SA; Reddy S; Hunter E; Robinson HL; Silvestri G; Amara RR; Derdeyn CA
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10780-5. PubMed ID: 26261312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination of Macaques with DNA Followed by Adenoviral Vectors Encoding Simian Immunodeficiency Virus (SIV) Gag Alone Delays Infection by Repeated Mucosal Challenge with SIV.
    Almond N; Berry N; Stebbings R; Preston M; Ham C; Page M; Ferguson D; Rose N; Li B; Mee ET; Hassall M; Stahl-Hennig C; Athanasopoulos T; Papagatsias T; Herath S; Benlahrech A; Dickson G; Meiser A; Patterson S
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31413132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.
    Vogel TU; Reynolds MR; Fuller DH; Vielhuber K; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Marthas ML; Erfle V; Wolinsky SM; Wang C; Allison DB; Rud EW; Wilson N; Montefiori D; Altman JD; Watkins DI
    J Virol; 2003 Dec; 77(24):13348-60. PubMed ID: 14645590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine-based, long-term, stable control of simian/human immunodeficiency virus 89.6PD replication in rhesus macaques.
    Yamamoto H; Kawada M; Tsukamoto T; Takeda A; Igarashi H; Miyazawa M; Naruse T; Yasunami M; Kimura A; Matano T
    J Gen Virol; 2007 Feb; 88(Pt 2):652-659. PubMed ID: 17251584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.
    Horton H; Vogel TU; Carter DK; Vielhuber K; Fuller DH; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Montefiori DC; Erfle V; Desrosiers RC; Wilson N; Picker LJ; Wolinsky SM; Wang C; Allison DB; Watkins DI
    J Virol; 2002 Jul; 76(14):7187-202. PubMed ID: 12072518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonhuman primate models for HIV/AIDS vaccine development.
    Sui Y; Gordon S; Franchini G; Berzofsky JA
    Curr Protoc Immunol; 2013 Oct; 102():12.14.1-12.14.30. PubMed ID: 24510515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dominant induction of vaccine antigen-specific cytotoxic T lymphocyte responses after simian immunodeficiency virus challenge.
    Takahara Y; Matsuoka S; Kuwano T; Tsukamoto T; Yamamoto H; Ishii H; Nakasone T; Takeda A; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Sakawaki H; Horiike M; Miura T; Igarashi T; Naruse TK; Kimura A; Matano T
    Biochem Biophys Res Commun; 2011 May; 408(4):615-9. PubMed ID: 21531211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AIDS vaccines. Long-lasting immunity conferred in monkeys.
    Cohen J
    Science; 2001 Mar; 291(5510):1879-81. PubMed ID: 11245180
    [No Abstract]   [Full Text] [Related]  

  • 36. Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.
    Lifson JD; Haigwood NL
    Cold Spring Harb Perspect Med; 2012 Jun; 2(6):a007310. PubMed ID: 22675663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
    Xiao P; Zhao J; Patterson LJ; Brocca-Cofano E; Venzon D; Kozlowski PA; Hidajat R; Demberg T; Robert-Guroff M
    J Virol; 2010 Jul; 84(14):7161-73. PubMed ID: 20444898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines.
    Staprans SI; Feinberg MB
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S5-32. PubMed ID: 15285703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.
    Mooij P; Nieuwenhuis IG; Knoop CJ; Doms RW; Bogers WM; Ten Haaft PJ; Niphuis H; Koornstra W; Bieler K; Köstler J; Morein B; Cafaro A; Ensoli B; Wagner R; Heeney JL
    J Virol; 2004 Apr; 78(7):3333-42. PubMed ID: 15016855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.